The following is the edited transcript and figures from a webinar presentation made by Dr. Heather Wakelee, medical oncologist and Associate Professor at Stanford Cancer Center, on Never-Smokers and Gender Differences in Lung Cancer.

Introduction to Molecular Markers

The third and final part of my conversation with Drs. Tom Hensing from North Shore Health System in Chicago and David Jackman from Dana Farber Cancer Institute in Boston covered a presentation of an Asian never-smoking woman with an advanced lung adenocarcinoma, the demographic picture most closely associated with potentially but not necessarily having an EGFR mutation or ALK rearrangement.

The second part of my conversation with Drs. Tom Hensing from North Shore Health System in Chicago and David Jackman from Dana Farber Cancer Institute in Boston covered a case of a relatively young, generally healthy woman diagnosed with a lung adenocarcinoma that turned out to be stage IV.

Last week, Dr. Ross Camidge from the University of Colorado joined me on a webinar entitled "One Size Does Not Fit All" in which he discussed the early work on ALK rearrangements and the novel agent PF-02341066 (now known as crizotinib) in particular, and the new era of molecularly defined practice of oncology in particular. This story has been widely considered to be among the most important in the field of lung cancer over the last few years, and Dr. Camidge did not disappoint.

We know that many people interested in the topics we discuss in our webinars may not be able to attend the live programs, but we're committed to offering our content to people as easily as possible. Accordingly, here is the podcast version of Dr. Pennell's very well received presentation on a range of molecular markers currently being used and others emerging in clinical trials as potential tools for the coming years.

Below you'll find the audio versions of the presentation.

This week’s New England Journal of Medicine includes not one but two seminal publications on EGFR mutation status, response to EGFR tyrosine kinase inhibitors (TKIs) and sequencing of therapy in advanced NSCLC.

Please Note: New Treatments Have Emerged Since this Original Post